BO39813 (#734)
Laufzeit: 01.01.2018 - 31.12.2020
imported
Kurzfassung
Phase Ib/II study of Cobimetinib administered as single agent and in combination with Venetoclax, with our without Atezolizumab, in patients with relapsed and refractory multiple myeloma
